high plasma total homocysteine concentration caused severe atherothrombotic disease and death in adolescents with homocystinuria. Folic acid, vitamin B 6 , and vitamin B 12 play critical rolesinthemetabolismofhomocysteine. 2 Treatment with large doses of folic acid, pyridoxine hydrochloride (vitamin B 6 ), and cyanocobalamin (vitamine B 12 ) lowered the homocysteine levels and dramatically reduced mortality in these patients. 3 In the last 30 years, numerous case-control and prospective studies have extended these findings to the general population and shown that high levels of homocysteine-albeit an order of magnitude lower than those in homocystinuria-are associated with vascular disease. [4] [5] [6] [7] On a parallel track, laboratory researchhasdemonstratedthathomocysteine causes oxidative stress, injures vascular endothelium, and stimulates formation of thrombi in vitro and in vivo.
1, [8] [9] [10] Although epidemiologic studies have confirmedtheassociationbetweenhomocysteineandcardiovascularrisk,interventional studies designed to lower homocysteine levels have not shown a consistent benefit on clinical outcomes. Several randomized controlled trials of lowering homocysteine with folic acid and B vitamins failed to find a reduction of major cardiovascular events or death in a variety of high-risk patients, [11] [12] [13] although a posthocanalysisinonestudyshowedthat a subgroup of stroke patients might have benefited from the intervention. 14 Patients with chronic kidney disease or end-stage renal disease (ESRD) have higher homocysteine levels than those in the foregoing trials. [15] [16] [17] They have extensive vascular disease, with estimates of annual mortality as high as 20%. [18] [19] [20] The cerebral and cardiovascular complications of the vascular disease, and, in some studies, thrombosis of the vascular access, a common and costly complication in ESRD, 21 are correlated with high homocysteine levels. 21 The characteristically high homocysteinelevels,extensivevasculardisease,and high mortality rates make this population particularly suitable to test the benefit of lowering homocysteine. We conducted a randomized controlled trial, sponsored by the Department of Veterans Affairs (VA) Cooperative Studies Program (Homocysteinemia in Kidney and End Stage Renal Disease [HOST]), to determine whether treatment with a combination of high-dose folic acid and vitamins B 6 and B 12 can reduce mortality and cardiovascular events in patients with advanced chronickidneydisease(ACKD)andESRD.
METHODS

Study Design
The details of the HOST study design have been described 22 and are summarized here. HOST was a multicenter, randomized, double-blind, placebocontrolled trial to determine whether treatment with folic acid plus pyridoxine and cyanocobalamin to lower plasma total homocysteine levels reduces allcause mortality and major vascular events in a high-risk population.
Study Population
Participants aged 21 years or older, with ESRD,receivingmaintenancehemodialysis or peritoneal dialysis, or with an estimated creatinine clearance of less than or equal to 30 mL/min (to convert creatinine clearance to mL/s, multiply by 0.0167) by the Cockcroft-Gault formula 23 (ACKD) were recruited from 36 participating VA medical centers. A plasma homocysteine level of 15 µmol/L or higher was also required. Race and ethnicity were based on patient self-report by using investigatordefined options. Race and ethnicity were assessed because they have been reported to be associated with the prevalence and outcomesofindividualswithchronickidney disease.
The human rights committee at the coordinating center and the institutional review boards of all participating sites approvedthestudy,andallstudyparticipants provided written informed consent.
Study Intervention
Participants were randomly assigned to receive a once-daily capsule containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride, and 2 mg of cyanocobalaminoranidentical-appearingplacebo capsule. Participants, investigators, laboratory staff, and the Endpoint AdjudicationCommitteewereblindedtotreatment assignment. The randomization scheme was stratified by site and disease strata (ESRD vs ACKD) and used a random permuted block design of varying block size. Participants in both groups were allowed to take additional vitamins containing no more than 1 mg of folate, if prescribed by their physicians as part of their general medical care.
Baseline and Follow-up Evaluations
At entry, demographic, clinical, and laboratory data, including plasma homocysteine and serum folic acid and vitamins B 6 and B 12 levels, were obtained and participants were given a 3-month supply of study drug. Participants returned to the local sites for evaluation at 3 months. A fasting blood sample was collected for homocysteine and folic acid determination. Participants were asked about hospitalizations,medicationadherence,studyoutcomes, and adverse events during the past 3 months and were given a new 3-month supplyofstudydrug.Allsubsequentquarterly follow-up evaluations were conducted by telephone (or, if necessary, by mail or e-mail) by study coordinators located at 2 centers. The central study coordinators attempted to verify all studyrelated outcome events reported by the participantsbysearchingtheVAelectronic records or by requesting records for non-VA hospitalizations. The participants receivedaquarterlysupplyofstudycapsules by mail from the VA Cooperative Studies Program Clinical Research Pharmacy. To assess adherence, participants were askedtoreturnthebottlewithunusedcapsules when they received a new bottle. In a representative substudy of 358 participants from 6 participating sites, blood samples were obtained annually for homocysteine, folic acid, vitamin B 6 , and vitamin B 12 determinations. The sites were selected according to number of participants (3 smaller and 3 larger sites) and were geographically dispersed.
Trial Outcomes
The primary study outcome was time to death from any cause. Secondary outcomes included time to myocardial infarction (MI), stroke, amputation of all or part of a lower extremity, and a composite of these 3 plus all-cause mortality. In addition, we assessed time to thrombosis of arteriovenous access (fistula or graft) in hemodialysis patients and time to initiation of dialysis in ACKD patients. All participants continued to be followed up and to receive their assigned treatment after a secondary outcome event.
Deaths were confirmed by hospital discharge summary, autopsy report, Medicare End Stage Renal Disease Death Notification,ordeathcertificate.Deathswere also tracked with the Beneficiary Identification and Records Locator Subsystem, a VA data file used to record death benefits and dates. 24 Fatal and nonfatal events were ascertained through self-reporting byparticipantsinresponsetospecificqueries during quarterly follow-up contacts and by review of the patient's VA medical record. Myocardial infarction was diagnosed when 2 of the following 3 criteriaweremet:typicalsymptoms,increased cardiacenzymelevels,anddiagnosticelectrocardiographicchanges. 25 Strokewasdefined as rapid onset of a persistent neurologic deficit attributed to an obstruction in the arterial system of the brain, providing the deficit was not known to be a result of cerebral hemorrhage, trauma, tumor, infection, or other nonthrombotic causes. 26 Thrombosis events were collected only for vascular accesses that were actuallybeingusedfordialysisanddidnot include events that occurred before dialysis initiation or that resulted in failure of access maturation.
An independent review committee, blinded to treatment assignment, adjudicated all secondary outcome events: MIs, strokes, and thromboses of the vascular access. Discharge summaries, neurologic examinations,imagingresults,cardiacenzyme reports, and electrocardiograms were obtained to verify hospitalization, diagnosis, and outcomes. Only definite or probable events were included in the analysis. An independent data and safety monitoringboardmonitoredthestudyfor safety and scientific integrity.
Laboratory Analyses
Plasma homocysteine level was determined with the Fluorescence Polarization Immunoassay/Abbott Axsym in kits provided by Abbott Laboratories (Abbott Park, Illinois). 27 The determination of serum concentrations of folic acid and vitamin B 12 (Bayer Direct Chemiluminescence Method [immunoassay]; Bayer Advia Centaur/Bayer Diagnostics, Tarrytown, New York) and vitamin B 6 (Alpco REA; RKVB 6 , Salem, New Hampshire) was performed in a central chemistry laboratory.
Statistical Analysis
The study was designed to enroll 2006 patients, with a median follow-up of 5 years to detect a relative risk reduction in time to event for the primary outcome of 17%, with 80% power, given a loss rate of approximately 1% per year, an annual event rate of 10.3% in the placebo group, and a 2-sided type I error of .05. The target number of events was 820.
All analyses were performed according to intention to treat. Participants who withdrew consent from all follow-up contacts and medical record reviews were included in the primary end point analysis but were censored from secondary outcome analyses at withdrawal. Survival curves for the 2 groups were estimated according to the Kaplan-Meier procedure and compared with the log-rank statistic.
The hazard ratios (vitamins relative to placebo) for all primary and secondary outcomes were calculated with the Cox proportional hazards regression model, adjusted for strata (ACKD vs ESRD). Cox models were also used to evaluate the treatment effect on the primary outcome in the prespecified subgroups of age, race, diabetes history, cardiac disease history, renal disease strata, and baseline homocysteine levels. Treatmentϫsubgroup interactions were performed to test for homogeneity.Additionalsensitivityanalyses of the treatment effect adjusted for baseline covariates were conducted to evaluate the stability of the study conclusions.AllreportedPvaluesare2-sidedand unadjusted for multiple comparisons. PՅ.05 was considered significant. SAS version 8.2 was used for all analyses (SAS Institute Inc, Cary, North Carolina). FIGURE 1) . In May 2006, the data and safety monitoring board recommended that the study be stopped because the required number of primary end points had been reached. Patient 
RESULTS
Between
Baseline Characteristics
The treatment and control groups were well balanced in baseline characteristics (TABLE 1). The mean (SD) estimated creatinine clearance of participants with ACKD was 21.6 (6.9) mL/ min by the Cockcroft-Gault method, and the estimated glomerular filtration rate was 18.3 (6.
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Effect of Intervention on Plasma Homocysteine and B Vitamin Levels
Themedianplasmahomocysteineandfolatelevelsatbaselineand3monthsarepre-sented in TABLE 2. The mean (SD) plasma homocysteine levels at baseline were 24.0 (7.7) and 24.2 (9.8) µmol/L for treatment and placebo groups, respectively. The mean homocysteine level was reduced by 6.2µmol/L(25.8%)inthetreatmentgroup at 3 months (PϽ.001); values for 36% (332) of the patients in the treatment group decreased into the normal range (Ͻ15 µmol/L). The mean decrease in homocysteine level of 0.4 µmol/L (1.7%) in the placebo group at 3 months was not significant (P=.14). There was a dramatic increase in the level of serum folic acid between baseline and 3 months in the treatment group but little change at 3 months in the placebo group (Table 2 ). In the cohort of 358 patients who had annual determinations of serum folic acid and plasma homocysteine levels, the effect of active treatment on homocysteine and folic acid at 3 months was maintained throughout the first 3 years of the study (the median follow-up time) (TABLE 3).
Primary End Point
Treatment had no effect on all-cause mortality (hazard ratio, 1.04; 95% confidence interval [CI], 0.91-1.18) (FIGURE 2;  TABLE 4 ). There were 884 deaths: 448 
Secondary End Points, Subgroups, and Adverse Events
Treatment had no effect on any of the major vascular events that comprise the secondary end points, the composite end point, the need to start maintenance dialysis, or thrombosis of the vascular access (Table 4) . Vascular access thrombosis occurred in 73 of the 336 patients (22%) with fistulae and 101 of the 221 patients (46%) with grafts at baseline. All-cause mortality did not differ significantly between the treatment and placebo groups in any of the subgroups examined (FIGURE 3) . There was no significant difference in the number and types of adverse events, includingseriousadverseevents,between the treatment and control groups. There werenostatisticallysignificantdifferences between the treatment groups for any of the potential adverse effects of the vitaminsthatwerespecificallyqueried,including gastrointestinal and dermatological events,headache,paresthesia,andfatigue, or for any self-reported adverse events, or hospital admissions.
Adherence
Among patients assigned to the vitamin treatment group, 90.3% reported taking study medication at 1 year, 87.6% at 2 years, and 85.3% at 3 years. In the placebo group, the figures were similar: 90.7% at 1 year, 87.2% at 2 years, and 86.5% at 3 years. A total of 73% in the treatment group and 74% in the placebo group reported never stopping their study medication. Counts of capsules in the returned bottles (77% of those dispensed) revealed that 90% of study capsules were taken by patients in both treatment and placebo groups.
COMMENT
Patients with chronic kidney disease have a high risk for complications of atherosclerosis, including increased mor- There were at total of 884 deaths.
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©2007 American Medical Association. All rights reserved. tality. Although traditional risk factors such as hypertension are more prevalent in this population, there has been increasing emphasis on the role of nontraditional risk factors such as anemia, hyperparathyroidism, and hyperhomocysteinemia. 29 The association of elevated homocysteine levels with risk of cardiovascular disease has drawn attention because of the nearly universal elevation of homocysteine in patients with chronic kidney disease to levels higher than that of any other patient population except those with homocystinuria, the epidemiologic correlation between homocysteine and cardiovascular risk in the chronic kidney disease population, [15] [16] [17] and the finding that ingestion of folic acid plus pyridoxine and cyanocobalamin lowers homocysteine levels in these patients. 16, 30 The results of our trial, however, indicate that although administration of large daily doses of folic acid plus pyridoxine and cyanocobalamin to patients with ACKD or ESRD lowered plasma homocysteine levels, it did not improve survival during a median of 3.2 years of follow-up. Furthermore, there was no significant decrease in the incidence of cardiovascular events or, in hemodialysis patients, the rate of thrombosis of the vascular access, a common event requiring hospitalization in these patients. 21 Recent reports of several large randomized trials in lower-risk patients without kidney disease, in whom smaller doses of vitaminswereusedandsmallerreductions in homocysteine levels were observed, have failed to show a benefit of vitamin supplementation: the Vitamin Intervention for Stroke Prevention, 13 the Heart OutcomesPreventionEvaluation(HOPE-2) study, 12 and the Norwegian Vitamin (NORVIT)trial. 11 Patientswithkidneydiseasehavehigherplasmahomocysteinelevels and a higher risk for cardiovascular events than patients included in the previously cited trials. There have been a limitednumberoftrialsofhomocysteinelowering in dialysis patients, but these trials were small and therefore underpowered to detect a clinically significant effect on mortality. [31] [32] [33] In our trial, however, which used large doses of vitamins, resulting in achangeinhomocysteinelevelstwicethat reportedinprevioustrials, [11] [12] [13] andwasadequately powered to detect a relative risk reduction in mortality of 17%, we failed to find a benefit of vitamin supplementation. In contrast to the NORVIT study, we did not observe an increased risk of vascular events in the treatment group. 11 What might account for the failure of the treatment in our study? Possibly the underlying burden of disease was too great for a measurable benefit from lowering homocysteine. A trial of statins in diabetic dialysis patients failed to show a mortality benefit despite lowering lowdensity lipoprotein cholesterol, 34 suggesting that even the reduction of some traditional risk factors may not be beneficial in this high-risk population. It may be that although homocysteine levels were substantially reduced, amelioration of the consequences of hyperhomocysteinemia requires lowering to normal levels, an effect that was achieved in only one-third of our participants, despite administration of the highest vitamin doses among homocysteinelowering studies reported to date. 35 Loscalzo, 10 commenting on the results of the NORVIT and HOPE-2 trials, has suggested that vitamin therapy may have had adverse effects that offset its homocysteine-lowering benefit.
The disparity between our findings and the epidemiologic literature showing an association between moderate increases in homocysteine and atherothrombotic disease could reflect an unrecognized adverse effect of the folic acid or vitamins but in all probability reflects the inherent limitations of observational studies. It has been suggested that homocysteine marks the existence of vascular disease rather than causes it 6, [10] [11] [12] [13] 32 ; yet in homocystinuria, vitamin therapy has an impressive benefit on mortality and cardiovascular events. 3 It may be that the relationship between homocysteine and vascular injury is nonlinear or that the potential for amelioration of the vascular injury is too slight in patients without homocystinuria to be detectable, particularly in patients with many other risk factors.
There are several limitations of this study. First, the population was nearly all male. The relationship between homocysteine and vascular disease and the response to vitamin therapy is similar in men and women.
2,5,36 The homocysteine levels and extent of vascular disease in the veterans in this trial are similar to those reported in nonveteran men and women with ACKD or ESRD 16, 18, 32, 33 ; we would therefore not expect that the enrollment of a predominantly male population accounts for our null results. Second, to achieve adequate power we enrolled both ACKD and ESRD patients. Jungers et al 16 reported an association of homocysteine and cardiovascular disease in chronic kidney disease similar to that in ESRD. In our study, homocysteine levels and prevalence of cardiovascular disease in the ACKD and ESRD strata were remarkably similar, as was the homocysteine-lowering effect of the vitamins. The proportion of participants who died during the study in the 2 groups was nearly identical. Although our study was not powered to examine these 2 strata separately, subgroup analyses did not show any difference in the treatment effect across strata. Third, follow-up contacts after the return visit at 3 months were not in person; thus, adherence and ascertainment of outcomes might have been incomplete. Previous studies have shown, however, that death can be reliably ascertained from death registries and patients' electronic records within the VA health care system. 24 Secondary outcomes of cardiovascular events may be less complete, but there is no a priori reason to expect differential ascertainment in the randomized groups.
In conclusion, treatment with high doses of folic acid and B vitamins did not reduce mortality or the incidence of cardiovascular events. Our findings do not support the administration of folic acid and B vitamin supplements to prevent vascular injury or improve survival in patients with ACKD or ESRD.
